Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. [electronic resource]
Producer: 20171003Description: 2756-2767 p. digitalISSN:- 1533-3450
- Adult
- Aged
- Aniline Compounds -- adverse effects
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis -- drug therapy
- Cyclophosphamide -- therapeutic use
- Double-Blind Method
- Drug Therapy, Combination -- adverse effects
- Female
- Glucocorticoids -- administration & dosage
- Humans
- Immunosuppressive Agents -- therapeutic use
- Male
- Middle Aged
- Nipecotic Acids -- adverse effects
- Prednisone -- administration & dosage
- Receptor, Anaphylatoxin C5a -- antagonists & inhibitors
- Rituximab -- therapeutic use
- Severity of Illness Index
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.